Clinical trial
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in…
NCT00047801 · Telik, Industry · Completed
Key facts
| NCT number | NCT00047801 |
|---|---|
| Title | Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer |
| Official title | Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer |
| Lead sponsor | Telik, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung |
| Intervention type | Drug |
| Interventions | TLK286 in combination with docetaxel |
| Enrollment | 28 |
| Start date | Oct 1, 2002 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Oct 21, 2002 |
| Last update posted | Jul 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: